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Abstract 
Modified nucleotides in messenger RNA (mRNA) have been discovered over 40 years ago, but 
until recently little was known about which transcripts contain them and what their function is. 
High-throughput sequencing approaches revealed a dynamic landscape of the "Epitranscriptome" 
for many mRNA modifications in various organisms from yeast to humans. Meanwhile, also 
many genes encoding mRNA modifying enzymes and auxiliary proteins have been identified 
yielding functional insights by reverse genetics into their role in development and disease.  
 
Abbreviations: A: adenosine, I: inosine, m6A: N6-methyladenosine, m1A: N1-methyladenosine, 
m5C: 5-methylcytosine, hm5C: 5-hydroxymethylcytosine 
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To date over 100 different nucleotide modifications have been identified in RNA (see: 
http://modomics.genesilico.pl/ and http://mods.rna.albany.edu). Most of these modifications are 
present in structural RNAs (e.g. tRNAs and rRNAs), but a few are also present in messenger 
RNAs (mRNAs) likely affecting all aspects of gene expression [1]. The most prominent 
modifications in mRNAs are inosine (I), pseudouridine (Ψ), N6-methyladenosine (m6A), N1-
methyladenosine (m1A), 5-methylcytosine (m5C) and 5-hydroxymethylcytosine (hm5C, Figure 
1). Here we recapitulate our current knowledge about the genes directing these modifications in 
humans and model organisms (Table 1) and what their roles are in development and disease 
(Table 2).  
 
Inosine 
The most common modification in mRNA is inosine (I) resulting from hydrolytic deamination of 
adenine (A) catalyzed by ADARs (Adenosine Deaminases Acting on RNA), which occurs in 
double stranded RNA (Figure 1). This process is called A-to-I editing and changes the coding 
because inosine behaves as guanosine and thus base-pairs with cytidine [2]. In protein-coding 
sequences, A-to-I editing is promoted by the formation of an imperfect fold-back RNA structure 
between the exonic region containing the editing site and the so-called editing-site 
complementary sequence (ECS), which is mainly found in intronic regions [3]. Therefore, it has 
been suggested that RNA editing predominantly occurs before splicing. In addition, ADAR2 
edits its own transcript to introduce a new 3' splice site, which in turn results in ADAR2 
truncation [1]. 
Vertebrates have three adar genes but one, adar3, appears to encode a catalytically inactive 
protein [2]. Common features of ADAR proteins are a conserved C-terminal catalytic domain, a 
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nuclear localization signal and up to three distinct dsRBDs (double-stranded RNA-binding 
domains). Whilst adar1 and adar2 are widely expressed, adar3 expression is restricted to the 
brain. The D. melanogaster genome encodes a single adar2-like gene (Adar) [4], while C. 
elegans has two distinct genes [5] and their loss results in neurological phenotypes. On the 
contrary, ADAR encoding genes are absent in plants, yeasts and filamentous fungi (Table 1) [6]. 
Historically, A-to-I editing had been found in transcripts of a few ion channel genes and has 
since expanded to about 80 protein-coding genes [2]. Although lethality of adar2 mutant mice 
suffering from epileptic seizures can be rescued by introducing the Q/R edited cDNA of the 
glutamate receptor GluR2 (GRIA2), recoding for example in AZIN1, COG3 and GRIA2 is 
functionally important [2, 7]. Since loss of adar1 in mice leads to aberrant activation of 
interferon signaling triggered by double-stranded RNA, it is thought that an important function 
of editing lies also in the immune system.  
Recent deep-sequencing revealed the largest number of inosines (approximately 15,000 in 
human genome) in non-coding repetitive regions, mainly in Alu elements, in 5′ and 3′ 
untranslated regions (UTRs) and long interspersed elements (LINE) [8]. Herein, the presence of 
inversely repetitive regions allows the formation of fold-back structures, which can be 
recognized by the dsRBDs of ADAR enzymes. 
One of the most interesting aspects of RNA editing is that I:U mismatch base pairs are less stable 
than A:U pair [9], therefore the deamination of adenosine in these duplexes destabilizes their 
overall structure. This feature of RNA editing appears to play an essential role in preventing an 
aberrant immune response in the presence of endogenous dsRNA that may otherwise trigger the 
interferon response. Accordingly, these I:U mismatches escape recognition by RIG-I (retinoic 
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acid-inducible gene I)-like cytoplasmic viral sensor proteins and thus protect cells from an 
aberrant interferon response [10]. 
Mutations that compromise A to I editing are linked to several disease phenotypes. The Aicardi-
Goutières syndrome (AGS), most frequently characterized by autosomal-recessive inherited 
mutations in adar1 gene, manifests as a childhood inflammatory disorder with aberrant 
interferon expression [11]. Another genetic disorder associated with adar1 is the rare autosomal-
dominant pigmentary genodermatosis dyschromatosis symmetrica hereditaria (DSH) disorder 
characterized by a mixture of hyper- and hypo-pigmented macules on hands and feet [12]. 
Hypo-editing of glutamate receptor GluR2 pre-mRNA by downregulated ADAR2 activity has 
also been associated with amyotrophic lateral sclerosis (ALS) and human glioma [13, 
14]. Editing in the serotonin receptor 5-HT2cR pre-mRNA has been linked to various psychiatric 
disorders including anxiety, bipolar disorder, autism, depression and schizophrenia [2]. 
In addition, dysregulation of both ADAR1 and/or ADAR2 editing in protein coding genes or 
miRNAs has also been linked to various cancers including hepatocellular carcinoma, chronic 
myeloid leukemia squamous cell carcinoma and glioblastoma [15-19]. Further to this, a global 
analysis of A to I editing revealed altered profiles in many cancers and indicates that editing 
selectively affects susceptibility to drug treatment [7]. 
 
Pseudouridine 
Pseudouridine (Ψ) represents the most abundant chemical modification detected in structural 
RNAs, but is also present in mRNAs. Ψ derives from enzymatic isomerization of uridine by 
rotation of the nitrogen at the C6 position (Figure 1) [20]. Pseudouridylation can be catalyzed 
through two different mechanisms: RNA-dependent and RNA-independent [21]. The former 
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process is carried out by RNA-protein complexes, consisting of a box H/ACA snoRNA, which 
guides four proteins including the putative rRNA pseudouridine synthase Cbf5 in yeast or DKC1 
in humans to introduce the modification site-specifically [21]. 
The RNA-independent mechanism for pseudouridylation relies on the evolutionary conserved 
PUS (pseudouridine synthase) domain enzymes (Table 1) [22]. In yeast seven PUS domain 
containing enzymes are present (PUS1-4, 6,7 and 9), Drosophila has 11, while the human 
genome contains 23 genes with a PUS domain. Recent pseudouridine profiling analyses in yeast 
and human cells revealed the presence of this modification predominantly in 5’UTRs and in the 
coding sequence of a few transcripts [23-25]. Further genetic analyses in yeast allowed for 
assigning individual pseudouridines to each of the seven pseudouridine synthases (PUS1-4, 6,7 
and 9), but all of these enzymes modify both mRNAs and structural RNAs [23]. In HEK293 cells 
most of the Ψ modifications are introduced by PUS1, PUS4 and PUS7 [25]. 
Interestingly, pseudouridine levels in several mRNAs are increased after heat shock and this 
involved cytoplasmic translocation of PUS7, highlighting a dynamic program under stress 
conditions, whereas Cbf5-mediated pseudouridylation is stress-independent. The function of Ψ 
in mRNA is not known, but might involve alteration of RNA structure, or might alternatively 
target modified mRNAs to heat shock-induced stress granules [25]. Recently, it has also been 
shown that Ψ can suppress translational termination if present in either of the three stop codons 
[26]. 
Defects in DKC1 (H/ACA ribonucleoprotein complex subunit 4) and PUS1 (tRNA 
pseudouridine synthase A) have been both associated to human disorders (Table 2). Germline 
mutations in the human dkc1 (dyskeratosis congenita 1) gene cause the bone marrow failure 
disorder dyskeratosis congenital l [27]. Associated with this disease is also poor maintenance of 
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telomeres due to lower pseudouridine levels in the ncRNA component of the telomerase complex 
(TERC) [25]. In addition, aberrant expression of dkc1 has also been linked to cancer pre-
disposition [28, 29].  
Noteworthy, various allelic variants of PUS1 show impaired mitochondrial and cytoplasmic 
tRNA pseudouridylation leading to various condition such as myopathy, lactic acidosis and 
sideroblastic anemia 1 (MLASA), a rare autosomal recessive oxidative phosphorylation disorder 
[30]. 
A role for snoRNA mediated pseudouridylation has been found in serotonin receptor 5-HT2cR 
alternative splicing regulation contributing to the disease of the Prader-Willi syndrome. These 
patients do not express the brain-specific C/D box snoRNA HBII52 due to an imprinting defect 
indicating that this complex involved in pseudouridylation has additional snoRNA guided roles 
beyond modifying mRNA [31, 32]. 
 
N6-methyladenosine 
The most abundant internal modification in mRNA is N6-methyladenosine (m6A, Figure 1) [33, 
34]. Although first discovered in the 70s, lack of molecular and genetic tools has hindered 
identifying its functional relevance until recent anti-m6A antibody pull-down and high-
throughput sequencing approaches [35-38]. These efforts revealed transcriptome-wide maps of 
m6A in humans, plants and yeast, but also indicated a high percentage of false positives due to 
the limited specificity of anti-m6A antibodies [37-40]. In humans, about 12,000 m6A sites were 
mapped on 7000 coding and 300 non-coding genes with an average of 3-5 sites per transcript 
[37]. Interestingly, m6A preferentially peaks in the 5’UTR and around the stop codon, but is also 
present in long exons in the consensus sequence RRACH (where R is a purine, and H is 
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adenosine, cytidine or uracil) [37, 38, 41, 42]. In accordance with their localization in UTRs, 
presence of m6A has been shown to affect mRNA stability and translation [43-45]. Although 
m6A is also found in introns, its exact roles in splicing regulation remain to be established. 
The proteins governing the dynamic m6A landscape can be divided into three classes: writers, 
readers, and erasers. Biochemical characterization of the human methylosome, the m6A writer, 
revealed two complexes of 200 kDa and 875 kDa containing the catalytic activity MT-A encoded 
by the mettl3 gene, which places the m6A epimark in single stranded RNA [46]. Recent 
proteomics and reconstitution assays identified further components including a second catalytic 
subunit METTL14, the splicing factors WTAP (Wilm's tumor associating protein) and Virilizer 
as well as a number of other proteins [47-50]. Orthologues of mettl3 and mettl14 are found in 
Drosophila, plants and budding yeast, but seem to be absent in worms and fission yeast [50, 51]. 
Loss of mettl3 results in embryonic lethality in mice and plants, while in S. cerevisiae, 
expression of the mettl3 orthologue inducer of meiosis4 (ime4) and consequently m6A are found 
only during meiosis [50, 52, 53]. Other functions include roles in mammalian embryonic stem 
cell renewal, the circadian clock and cap independent translation for directing the heat-shock 
response [52, 54-57].  
Readers of the m6A epimark belong to the YT521-B homology (YTH) protein family. The YTH 
domain has a fifty fold higher affinity towards m6A compared to unmodified adenosine. Humans 
have five YTH proteins (YTHDF1-3 and YTHDC1 and 2), Drosophila has two (CG6422 and 
YT521-B) and S. cerevisiae has one (Mrb1), while plants have thirteen orthologues [33]. 
Intriguingly, the fission yeast YTH orthologue Mmi1 binds RNA in a different mode than the 
other YTH proteins consistent with the absence of m6A in mRNA in this organism [58]. 
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While reader proteins directly bind the modified nucleotide, m6A has also been shown to 
promote RNA structural remodeling to favor recruitment of the RNA binding protein HNRNPC 
in a stem loop of the MALAT1 non-coding RNA [59].  
Eraser proteins are m6A demethylases making this modification completely reversible. Currently 
two such proteins are known: Fat mass and obesity associated (FTO) and ALKBH5, a member of 
the Fe2/α-ketoglutarate-dependent dioxygenase family [60, 61].  
Whereas alkbh5 knockout mice have impaired male fertility [62], alterations in FTO expression 
have been connected to altered energy metabolism leading to obesity, type 2 diabetes, growth 
retardation, developmental delay, facial dysmorphism and cancer [63-66]. 
 
N1-methyladenosine 
Yet another modification analysed for its genome-wide occurrence is N1-methyladenosine 
(m1A) [67, 68]. Elegantly, m1A can be converted to m6A by the Dimroth reaction and then 
analysed using the m6A antibody. This analysis revealed a dynamic m1A landscape with a 
predominant peak near the start codon in human and yeast mRNA in response to cellular stress. 
Noteworthy, the m1A modification harbours a positive charge under physiological conditions. 
This may affect the canonical base pairing, altering secondary and tertiary structure, or affect 
RNA-protein interactions. In contrast to the m6A modification, m1A leads to abortive reverse 
transcription, which can be employed to validate this modification [69]. 
While the catalytic entity responsible for installing m1A is still not known, overexpression of the 
alkbh3 gene results in decreased m1A levels. This makes ALKBH3 a likely candidate for 
demethylating m1A in mRNAs [67]. 
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5-methylcytosine and 5-hydroxymethylcytosine 
The methyl group in 5-methylcytosine (m5C) prevents the conversion to uracil by bisulfite 
treatment. Applying this feature in combination with high-throughput sequencing detected a 
considerable number of m5C in mRNA [70]. In mRNA, m5C is mainly present in untranslated 
regions in the proximity of Argonaute family protein binding sites suggesting roles in mRNA 
stability and translation [70]. 
The only enzyme currently known to methylate cytosine in mRNA is NSUN2 (NOP2/Sun RNA 
methyltransferase family member 2) [70, 71]. Evolutionary conserved NSUN2 localizes to the 
nucleus, but in addition to mRNA also methylates cytosines in tRNAs as revealed by a mutant 
NSUN2 protein tethering itself to the site of methylation (Table 1)[72].  
NSUN2 is required for stem cell differentiation and cell proliferation, but has also been linked to 
human cancers [71, 73-76]. In addition, methylation of the mRNA for intracellular cell adhesion 
molecule (ICAM-1) promotes inflammation via increased translation [77]. In accordance with 
NSUN2’s increased expression in the brain, mutations have been identified that cause 
intellectual disability [78]. 
Although Drosophila seems not have m5C DNA methylation, its genome contains a Ten-eleven-
translocation (Tet) orthologue involved in DNA demethylation in vertebrates via hydroxylation 
of the methylgroup, which is then further modified to 5-formylcytosine and 5-carboxylcytosine 
leading to glycosylation and removal via DNA excision repair. This paradox is explained by the 
capacity of human TET3, but not TET1 or TET2, to hydroxylate m5C in RNA [79]. 
Accordingly, hm5C can be detected in RNA of animals and plants, but at lower levels than m5C 
[80]. Using an antibody against hm5C and high throughput sequencing 3058 hm5C methylation 
sites have been detected in 1597 transcripts in Drosophila S2 cells [81]. Although these levels 
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are low, hm5C in mRNA is functionally relevant as Drosophila tet mutants die during pupal 
development and show defects in neuroblast proliferation [81]. 
Noteworthy, tet-null ES cells genetically deprived of all TET enzymes, still show detectable 
levels of hm5C, suggesting that m5C oxidation can also be catalyzed by different enzymes or 
induced by cellular reactive oxygen species. Accordingly, the hm5C modification is also 
detectable in C. elegans and A. thaliana, which do not have orthologues of TET in their genomes 
[79]. 
 
Conclusions 
Various mRNA modifications are present from yeast to humans and the factors installing these 
modifications are evolutionarily conserved indicating ancient mechanisms to regulate gene 
expression at the level of the mRNA. Recent high-throughput sequencing approaches have 
brought about a dynamic landscape for many mRNA modifications initiating the new field of 
epitranscriptomics. Surely, more mRNA modifications will turn up, but future challenges lie in 
connecting the dynamic nature of mRNA modifications to regulatory pathways relevant to 
development and human disease. 
Dezi et al. 12 
References 
 
1 Soller, M. (2006) Pre-messenger RNA processing and its regulation: a genomic perspective. Cell 
Mol Life Sci. 63, 796-819 
2 Nishikura, K. (2016) A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol 
Cell Biol. 17, 83-96 
3 Bass, B. L. (2002) RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem. 
71, 817-846 
4 Palladino, M. J., Keegan, L. P., O'Connell, M. A. and Reenan, R. A. (2000) A-to-I pre-mRNA 
editing in Drosophila is primarily involved in adult nervous system function and integrity. Cell. 102, 437-
449 
5 Tonkin, L. A., Saccomanno, L., Morse, D. P., Brodigan, T., Krause, M. and Bass, B. L. (2002) 
RNA editing by ADARs is important for normal behavior in Caenorhabditis elegans. EMBO J. 21, 6025-
6035 
6 Jin, Y., Zhang, W. and Li, Q. (2009) Origins and evolution of ADAR-mediated RNA editing. 
IUBMB Life. 61, 572-578 
7 Han, L., Diao, L., Yu, S., Xu, X., Li, J., Zhang, R., Yang, Y., Werner, H. M., Eterovic, A. K., 
Yuan, Y., Nair, N., Minelli, R., Tsang, Y. H., Cheung, L. W., Jeong, K. J., Roszik, J., Ju, Z., Woodman, 
S. E., Lu, Y., Scott, K. L., Li, J. B., Mills, G. B. and Liang, H. (2015) The Genomic Landscape and 
Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 28, 515-528 
8 Ramaswami, G., Lin, W., Piskol, R., Tan, M. H., Davis, C. and Li, J. B. (2012) Accurate 
identification of human Alu and non-Alu RNA editing sites. Nat Methods. 9, 579-581 
9 Strobel, S. A., Cech, T. R., Usman, N. and Beigelman, L. (1994) The 2,6-diaminopurine 
riboside.5-methylisocytidine wobble base pair: an isoenergetic substitution for the study of G.U pairs in 
RNA. Biochemistry. 33, 13824-13835 
Dezi et al. 13 
10 Mannion, N. M., Greenwood, S. M., Young, R., Cox, S., Brindle, J., Read, D., Nellaker, C., 
Vesely, C., Ponting, C. P., McLaughlin, P. J., Jantsch, M. F., Dorin, J., Adams, I. R., Scadden, A. D. J., 
Ohman, M., Keegan, L. P. and O'Connell, M. A. (2014) The RNA-Editing Enzyme ADAR1 Controls 
Innate Immune Responses to RNA. Cell Reports. 9, 1482-1494 
11 Rice, G. I., Kasher, P. R., Forte, G. M., Mannion, N. M., Greenwood, S. M., Szynkiewicz, M., 
Dickerson, J. E., Bhaskar, S. S., Zampini, M., Briggs, T. A., Jenkinson, E. M., Bacino, C. A., Battini, R., 
Bertini, E., Brogan, P. A., Brueton, L. A., Carpanelli, M., De Laet, C., de Lonlay, P., del Toro, M., 
Desguerre, I., Fazzi, E., Garcia-Cazorla, A., Heiberg, A., Kawaguchi, M., Kumar, R., Lin, J. P., Lourenco, 
C. M., Male, A. M., Marques, W., Jr., Mignot, C., Olivieri, I., Orcesi, S., Prabhakar, P., Rasmussen, M., 
Robinson, R. A., Rozenberg, F., Schmidt, J. L., Steindl, K., Tan, T. Y., van der Merwe, W. G., 
Vanderver, A., Vassallo, G., Wakeling, E. L., Wassmer, E., Whittaker, E., Livingston, J. H., Lebon, P., 
Suzuki, T., McLaughlin, P. J., Keegan, L. P., O'Connell, M. A., Lovell, S. C. and Crow, Y. J. (2012) 
Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat 
Genet. 44, 1243-1248 
12 Miyamura, Y., Suzuki, T., Kono, M., Inagaki, K., Ito, S., Suzuki, N. and Tomita, Y. (2003) 
Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis 
symmetrica hereditaria. Am J Hum Genet. 73, 693-699 
13 Kawahara, Y., Ito, K., Sun, H., Aizawa, H., Kanazawa, I. and Kwak, S. (2004) Glutamate 
receptors: RNA editing and death of motor neurons. Nature. 427, 801 
14 Maas, S., Patt, S., Schrey, M. and Rich, A. (2001) Underediting of glutamate receptor GluR-B 
mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 98, 14687-14692 
15 Nemlich, Y., Greenberg, E., Ortenberg, R., Besser, M. J., Barshack, I., Jacob-Hirsch, J., Jacoby, 
E., Eyal, E., Rivkin, L., Prieto, V. G., Chakravarti, N., Duncan, L. M., Kallenberg, D. M., Galun, E., 
Bennett, D. C., Amariglio, N., Bar-Eli, M., Schachter, J., Rechavi, G. and Markel, G. (2013) MicroRNA-
mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 123, 2703-2718 
Dezi et al. 14 
16 Tomaselli, S., Galeano, F., Alon, S., Raho, S., Galardi, S., Polito, V. A., Presutti, C., Vincenti, S., 
Eisenberg, E., Locatelli, F. and Gallo, A. (2015) Modulation of microRNA editing, expression and 
processing by ADAR2 deaminase in glioblastoma. Genome Biol. 16, 5 
17 Qin, Y. R., Qiao, J. J., Chan, T. H., Zhu, Y. H., Li, F. F., Liu, H., Fei, J., Li, Y., Guan, X. Y. and 
Chen, L. (2014) Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell 
carcinoma. Cancer Res. 74, 840-851 
18 Chan, T. H., Lin, C. H., Qi, L., Fei, J., Li, Y., Yong, K. J., Liu, M., Song, Y., Chow, R. K., Ng, V. 
H., Yuan, Y. F., Tenen, D. G., Guan, X. Y. and Chen, L. (2014) A disrupted RNA editing balance 
mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 
63, 832-843 
19 Jiang, Q., Crews, L. A., Barrett, C. L., Chun, H. J., Court, A. C., Isquith, J. M., Zipeto, M. A., 
Goff, D. J., Minden, M., Sadarangani, A., Rusert, J. M., Dao, K. H., Morris, S. R., Goldstein, L. S., 
Marra, M. A., Frazer, K. A. and Jamieson, C. H. (2012) ADAR1 promotes malignant progenitor 
reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 110, 1041-1046 
20 Hoang, C. and Ferre-D'Amare, A. R. (2001) Cocrystal structure of a tRNA Psi55 pseudouridine 
synthase: nucleotide flipping by an RNA-modifying enzyme. Cell. 107, 929-939 
21 Karijolich, J., Yi, C. and Yu, Y. T. (2015) Transcriptome-wide dynamics of RNA 
pseudouridylation. Nat Rev Mol Cell Biol. 16, 581-585 
22 Hamma, T. and Ferre-D'Amare, A. R. (2006) Pseudouridine synthases. Chem Biol. 13, 1125-
1135 
23 Carlile, T. M., Rojas-Duran, M. F., Zinshteyn, B., Shin, H., Bartoli, K. M. and Gilbert, W. V. 
(2014) Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. 
Nature. 515, 143-146 
24 Lovejoy, A. F., Riordan, D. P. and Brown, P. O. (2014) Transcriptome-wide mapping of 
pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae. PLoS One. 9, e110799 
Dezi et al. 15 
25 Schwartz, S., Bernstein, D. A., Mumbach, M. R., Jovanovic, M., Herbst, R. H., Leon-Ricardo, B. 
X., Engreitz, J. M., Guttman, M., Satija, R., Lander, E. S., Fink, G. and Regev, A. (2014) Transcriptome-
wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell. 159, 
148-162 
26 Karijolich, J. and Yu, Y. T. (2011) Converting nonsense codons into sense codons by targeted 
pseudouridylation. Nature. 474, 395-398 
27 Heiss, N. S., Knight, S. W., Vulliamy, T. J., Klauck, S. M., Wiemann, S., Mason, P. J., Poustka, 
A. and Dokal, I. (1998) X-linked dyskeratosis congenita is caused by mutations in a highly conserved 
gene with putative nucleolar functions. Nature Genetics. 19, 32-38 
28 Bellodi, C., Krasnykh, O., Haynes, N., Theodoropoulou, M., Peng, G., Montanaro, L. and 
Ruggero, D. (2010) Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and 
contributes to pituitary tumorigenesis. Cancer Res. 70, 6026-6035 
29 Sieron, P., Hader, C., Hatina, J., Engers, R., Wlazlinski, A., Muller, M. and Schulz, W. A. (2009) 
DKC1 overexpression associated with prostate cancer progression. Br J Cancer. 101, 1410-1416 
30 Patton, J. R., Bykhovskaya, Y., Mengesha, E., Bertolotto, C. and Fischel-Ghodsian, N. (2005) 
Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine 
synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem. 280, 19823-
19828 
31 Kishore, S. and Stamm, S. (2006) The snoRNA HBII-52 regulates alternative splicing of the 
serotonin receptor 2C. Science. 311, 230-232 
32 Falaleeva, M., Pages, A., Matuszek, Z., Hidmi, S., Agranat-Tamir, L., Korotkov, K., Nevo, Y., 
Eyras, E., Sperling, R. and Stamm, S. (2016) Dual function of C/D box small nucleolar RNAs in rRNA 
modification and alternative pre-mRNA splicing. Proc Natl Acad Sci U S A. 113, E1625-1634 
33 Fu, Y., Dominissini, D., Rechavi, G. and He, C. (2014) Gene expression regulation mediated 
through reversible m(6)A RNA methylation. Nature Reviews Genetics. 15, 293-306 
Dezi et al. 16 
34 Meyer, K. D. and Jaffrey, S. R. (2014) The dynamic epitranscriptome: N6-methyladenosine and 
gene expression control. Nat Rev Mol Cell Biol. 15, 313-326 
35 Perry, R. P. and Kelley, D. E. (1974) Existence of methylated messenger RNA in mouse L cells. 
Cell. 1, 37-42 
36 Desrosiers, R., Friderici, K. and Rottman, F. (1974) Identification of methylated nucleosides in 
messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 71, 3971-3975 
37 Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., 
Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., Sorek, R. and Rechavi, G. 
(2012) Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 485, 
201-206 
38 Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E. and Jaffrey, S. R. (2012) 
Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell. 
149, 1635-1646 
39 Luo, G. Z., MacQueen, A., Zheng, G., Duan, H., Dore, L. C., Lu, Z., Liu, J., Chen, K., Jia, G., 
Bergelson, J. and He, C. (2014) Unique features of the m6A methylome in Arabidopsis thaliana. Nat 
Commun. 5, 5630 
40 Schwartz, S., Agarwala, S. D., Mumbach, M. R., Jovanovic, M., Mertins, P., Shishkin, A., 
Tabach, Y., Mikkelsen, T. S., Satija, R., Ruvkun, G., Carr, S. A., Lander, E. S., Fink, G. R. and Regev, A. 
(2013) High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program 
in yeast meiosis. Cell. 155, 1409-1421 
41 Linder, B., Grozhik, A. V., Olarerin-George, A. O., Meydan, C., Mason, C. E. and Jaffrey, S. R. 
(2015) Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat 
Methods. 12, 767-772 
42 Ke, S., Alemu, E. A., Mertens, C., Gantman, E. C., Fak, J. J., Mele, A., Haripal, B., Zucker-
Scharff, I., Moore, M. J., Park, C. Y., Vagbo, C. B., Kussnierczyk, A., Klungland, A., Darnell, J. E., Jr. 
Dezi et al. 17 
and Darnell, R. B. (2015) A majority of m6A residues are in the last exons, allowing the potential for 3' 
UTR regulation. Genes Dev. 29, 2037-2053 
43 Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., 
Ren, B., Pan, T. and He, C. (2014) N6-methyladenosine-dependent regulation of messenger RNA 
stability. Nature. 505, 117-120 
44 Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., Weng, X., Chen, K., Shi, H. and 
He, C. (2015) N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 161, 1388-
1399 
45 Liu, N. and Pan, T. (2016) N-methyladenosine-encoded epitranscriptomics. Nat Struct Mol Biol. 
23, 98-102 
46 Bokar, J. A., Shambaugh, M. E., Polayes, D., Matera, A. G. and Rottman, F. M. (1997) 
Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-
methyltransferase. RNA. 3, 1233-1247 
47 Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z., Deng, X., Dai, Q., 
Chen, W. and He, C. (2014) A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-
adenosine methylation. Nat Chem Biol. 10, 93-95 
48 Ping, X. L., Sun, B. F., Wang, L., Xiao, W., Yang, X., Wang, W. J., Adhikari, S., Shi, Y., Lv, Y., 
Chen, Y. S., Zhao, X., Li, A., Yang, Y., Dahal, U., Lou, X. M., Liu, X., Huang, J., Yuan, W. P., Zhu, X. 
F., Cheng, T., Zhao, Y. L., Wang, X., Rendtlew Danielsen, J. M., Liu, F. and Yang, Y. G. (2014) 
Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 
24, 177-189 
49 Horiuchi, K., Kawamura, T., Iwanari, H., Ohashi, R., Naito, M., Kodama, T. and Hamakubo, T. 
(2013) Identification of Wilms' tumor 1-associating protein complex and its role in alternative splicing 
and the cell cycle. J Biol Chem. 288, 33292-33302 
Dezi et al. 18 
50 Zhong, S., Li, H., Bodi, Z., Button, J., Vespa, L., Herzog, M. and Fray, R. G. (2008) MTA is an 
Arabidopsis messenger RNA adenosine methylase and interacts with a homolog of a sex-specific splicing 
factor. Plant Cell. 20, 1278-1288 
51 Agarwala, S. D., Blitzblau, H. G., Hochwagen, A. and Fink, G. R. (2012) RNA methylation by 
the MIS complex regulates a cell fate decision in yeast. PLoS Genet. 8, e1002732 
52 Geula, S., Moshitch-Moshkovitz, S., Dominissini, D., Mansour, A. A., Kol, N., Salmon-Divon, 
M., Hershkovitz, V., Peer, E., Mor, N., Manor, Y. S., Ben-Haim, M. S., Eyal, E., Yunger, S., Pinto, Y., 
Jaitin, D. A., Viukov, S., Rais, Y., Krupalnik, V., Chomsky, E., Zerbib, M., Maza, I., Rechavi, Y., 
Massarwa, R., Hanna, S., Amit, I., Levanon, E. Y., Amariglio, N., Stern-Ginossar, N., Novershtern, N., 
Rechavi, G. and Hanna, J. H. (2015) Stem cells. m6A mRNA methylation facilitates resolution of naive 
pluripotency toward differentiation. Science. 347, 1002-1006 
53 Clancy, M. J., Shambaugh, M. E., Timpte, C. S. and Bokar, J. A. (2002) Induction of sporulation 
in Saccharomyces cerevisiae leads to the formation of N6-methyladenosine in mRNA: a potential 
mechanism for the activity of the IME4 gene. Nucleic Acids Res. 30, 4509-4518 
54 Fustin, J. M., Doi, M., Yamaguchi, Y., Hida, H., Nishimura, S., Yoshida, M., Isagawa, T., 
Morioka, M. S., Kakeya, H., Manabe, I. and Okamura, H. (2013) RNA-methylation-dependent RNA 
processing controls the speed of the circadian clock. Cell. 155, 793-806 
55 Zhao, B. S. and He, C. (2015) Fate by RNA methylation: m6A steers stem cell pluripotency. 
Genome Biol. 16, 43 
56 Zhou, J., Wan, J., Gao, X., Zhang, X., Jaffrey, S. R. and Qian, S. B. (2015) Dynamic m(6)A 
mRNA methylation directs translational control of heat shock response. Nature. 526, 591-594 
57 Meyer, K. D., Patil, D. P., Zhou, J., Zinoviev, A., Skabkin, M. A., Elemento, O., Pestova, T. V., 
Qian, S. B. and Jaffrey, S. R. (2015) 5' UTR m(6)A Promotes Cap-Independent Translation. Cell. 163, 
999-1010 
Dezi et al. 19 
58 Starck, S. R., Tsai, J. C., Chen, K., Shodiya, M., Wang, L., Yahiro, K., Martins-Green, M., 
Shastri, N. and Walter, P. (2016) Translation from the 5' untranslated region shapes the integrated stress 
response. Science. 351, aad3867 
59 Liu, N., Dai, Q., Zheng, G., He, C., Parisien, M. and Pan, T. (2015) N(6)-methyladenosine-
dependent RNA structural switches regulate RNA-protein interactions. Nature. 518, 560-564 
60 Jia, G. F., Fu, Y., Zhao, X., Dai, Q., Zheng, G. Q., Yang, Y., Yi, C. Q., Lindahl, T., Pan, T., 
Yang, Y. G. and He, C. (2011) N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-
associated FTO. Nature Chemical Biology. 7, 885-887 
61 Zheng, G. Q., Dahl, J. A., Niu, Y. M., Fedorcsak, P., Huang, C. M., Li, C. J., Vagbo, C. B., Shi, 
Y., Wang, W. L., Song, S. H., Lu, Z. K., Bosmans, R. P. G., Dai, Q., Hao, Y. J., Yang, X., Zhao, W. M., 
Tong, W. M., Wang, X. J., Bogdan, F., Furu, K., Fu, Y., Jia, G. F., Zhao, X., Liu, J., Krokan, H. E., 
Klungland, A., Yang, Y. G. and He, C. (2013) ALKBH5 Is a Mammalian RNA Demethylase that Impacts 
RNA Metabolism and Mouse Fertility. Molecular Cell. 49, 18-29 
62 Landfors, M., Nakken, S., Fusser, M., Dahl, J. A., Klungland, A. and Fedorcsak, P. (2016) 
Sequencing of FTO and ALKBH5 in men undergoing infertility work-up identifies infertility-associated 
variant and two missense mutations. Fertil Steril 
63 Dina, C., Meyre, D., Gallina, S., Durand, E., Korner, A., Jacobson, P., Carlsson, L. M., Kiess, W., 
Vatin, V., Lecoeur, C., Delplanque, J., Vaillant, E., Pattou, F., Ruiz, J., Weill, J., Levy-Marchal, C., 
Horber, F., Potoczna, N., Hercberg, S., Le Stunff, C., Bougneres, P., Kovacs, P., Marre, M., Balkau, B., 
Cauchi, S., Chevre, J. C. and Froguel, P. (2007) Variation in FTO contributes to childhood obesity and 
severe adult obesity. Nat Genet. 39, 724-726 
64 Boissel, S., Reish, O., Proulx, K., Kawagoe-Takaki, H., Sedgwick, B., Yeo, G. S. H., Meyre, D., 
Golzio, C., Molinari, F., Kadhom, N., Etchevers, H. C., Saudek, V., Farooqi, I. S., Froguel, P., Lindahl, 
T., O'Rahilly, S., Munnich, A. and Colleaux, L. (2009) Loss-of-Function Mutation in the Dioxygenase-
Encoding FTO Gene Causes Severe Growth Retardation and Multiple Malformations. American Journal 
of Human Genetics. 85, 106-111 
Dezi et al. 20 
65 Xiao, S., Zeng, X., Fan, Y., Su, Y., Ma, Q., Zhu, J. and Yao, H. (2016) Gene Polymorphism 
Association with Type 2 Diabetes and Related Gene-Gene and Gene-Environment Interactions in a 
Uyghur Population. Medical Science Monitor. 22, 474-487 
66 Church, C., Moir, L., McMurray, F., Girard, C., Banks, G. T., Teboul, L., Wells, S., Bruning, J. 
C., Nolan, P. M., Ashcroft, F. M. and Cox, R. D. (2010) Overexpression of Fto leads to increased food 
intake and results in obesity. Nat Genet. 42, 1086-1092 
67 Dominissini, D., Nachtergaele, S., Moshitch-Moshkovitz, S., Peer, E., Kol, N., Ben-Haim, M. S., 
Dai, Q., Di Segni, A., Salmon-Divon, M., Clark, W. C., Zheng, G., Pan, T., Solomon, O., Eyal, E., 
Hershkovitz, V., Han, D., Dore, L. C., Amariglio, N., Rechavi, G. and He, C. (2016) The dynamic N(1)-
methyladenosine methylome in eukaryotic messenger RNA. Nature. 530, 441-446 
68 Li, X., Xiong, X., Wang, K., Wang, L., Shu, X., Ma, S. and Yi, C. (2016) Transcriptome-wide 
mapping reveals reversible and dynamic N-methyladenosine methylome. Nat Chem Biol 
69 Tserovski, L., Marchand, V., Hauenschild, R., Blanloeil-Oillo, F., Helm, M. and Motorin, Y. 
(2016) High-throughput sequencing for 1-methyladenosine (mA) mapping in RNA. Methods 
70 Squires, J. E., Patel, H. R., Nousch, M., Sibbritt, T., Humphreys, D. T., Parker, B. J., Suter, C. M. 
and Preiss, T. (2012) Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. 
Nucleic Acids Res. 40, 5023-5033 
71 Hussain, S., Aleksic, J., Blanco, S., Dietmann, S. and Frye, M. (2013) Characterizing 5-
methylcytosine in the mammalian epitranscriptome. Genome Biol. 14, 215 
72 Hussain, S., Sajini, A. A., Blanco, S., Dietmann, S., Lombard, P., Sugimoto, Y., Paramor, M., 
Gleeson, J. G., Odom, D. T., Ule, J. and Frye, M. (2013) NSun2-mediated cytosine-5 methylation of vault 
noncoding RNA determines its processing into regulatory small RNAs. Cell Rep. 4, 255-261 
73 Frye, M. and Watt, F. M. (2006) The RNA methyltransferase Misu (NSun2) mediates Myc-
induced proliferation and is upregulated in tumors. Curr Biol. 16, 971-981 
Dezi et al. 21 
74 Frye, M., Dragoni, I., Chin, S. F., Spiteri, I., Kurowski, A., Provenzano, E., Green, A., Ellis, I. O., 
Grimmer, D., Teschendorff, A., Zouboulis, C. C., Caldas, C. and Watt, F. M. (2009) Genomic gain of 
5p15 leads to over-expression of Misu (NSUN2) in breast cancer. Cancer Lett. 289, 71-80 
75 Hussain, S., Benavente, S. B., Nascimento, E., Dragoni, I., Kurowski, A., Gillich, A., 
Humphreys, P. and Frye, M. (2009) The nucleolar RNA methyltransferase Misu (NSun2) is required for 
mitotic spindle stability. J Cell Biol. 186, 27-40 
76 Blanco, S., Kurowski, A., Nichols, J., Watt, F. M., Benitah, S. A. and Frye, M. (2011) The RNA-
methyltransferase Misu (NSun2) poises epidermal stem cells to differentiate. PLoS Genet. 7, e1002403 
77 Luo, Y., Feng, J., Xu, Q., Wang, W. and Wang, X. (2016) NSun2 Deficiency Protects 
Endothelium From Inflammation via mRNA Methylation of ICAM-1. Circ Res. 118, 944-956 
78 Abbasi-Moheb, L., Mertel, S., Gonsior, M., Nouri-Vahid, L., Kahrizi, K., Cirak, S., Wieczorek, 
D., Motazacker, M. M., Esmaeeli-Nieh, S., Cremer, K., Weissmann, R., Tzschach, A., Garshasbi, M., 
Abedini, S. S., Najmabadi, H., Ropers, H. H., Sigrist, S. J. and Kuss, A. W. (2012) Mutations in NSUN2 
cause autosomal-recessive intellectual disability. Am J Hum Genet. 90, 847-855 
79 Fu, L., Guerrero, C. R., Zhong, N., Amato, N. J., Liu, Y., Liu, S., Cai, Q., Ji, D., Jin, S. G., 
Niedernhofer, L. J., Pfeifer, G. P., Xu, G. L. and Wang, Y. (2014) Tet-mediated formation of 5-
hydroxymethylcytosine in RNA. J Am Chem Soc. 136, 11582-11585 
80 Huber, S. M., van Delft, P., Mendil, L., Bachman, M., Smollett, K., Werner, F., Miska, E. A. and 
Balasubramanian, S. (2015) Formation and abundance of 5-hydroxymethylcytosine in RNA. 
Chembiochem. 16, 752-755 
81 Delatte, B., Wang, F., Ngoc, L. V., Collignon, E., Bonvin, E., Deplus, R., Calonne, E., Hassabi, 
B., Putmans, P., Awe, S., Wetzel, C., Kreher, J., Soin, R., Creppe, C., Limbach, P. A., Gueydan, C., 
Kruys, V., Brehm, A., Minakhina, S., Defrance, M., Steward, R. and Fuks, F. (2016) RNA biochemistry. 
Transcriptome-wide distribution and function of RNA hydroxymethylcytosine. Science. 351, 282-285 
82 Giordano, E., Peluso, I., Senger, S. and Furia, M. (1999) minifly, a Drosophila gene required for 
ribosome biogenesis. J Cell Biol. 144, 1123-1133 
Dezi et al. 22 
83 Chen, L., Li, Y., Lin, C. H., Chan, T. H., Chow, R. K., Song, Y., Liu, M., Yuan, Y. F., Fu, L., 
Kong, K. L., Qi, L., Zhang, N., Tong, A. H., Kwong, D. L., Man, K., Lo, C. M., Lok, S., Tenen, D. G. 
and Guan, X. Y. (2013) Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat 
Med. 19, 209-216 
84 Liu, Q., Jiang, L., Liu, W. L., Kang, X. J., Ao, Y., Sun, M., Luo, Y., Song, Y., Lo, W. H. and 
Zhang, X. (2006) Two novel mutations and evidence for haploinsufficiency of the ADAR gene in 
dyschromatosis symmetrica hereditaria. Br J Dermatol. 154, 636-642 
85 Gaisler-Salomon, I., Kravitz, E., Feiler, Y., Safran, M., Biegon, A., Amariglio, N. and Rechavi, 
G. (2014) Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease. Neurobiol 
Aging. 35, 1785-1791 
86 Hideyama, T., Yamashita, T., Aizawa, H., Tsuji, S., Kakita, A., Takahashi, H. and Kwak, S. 
(2012) Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. 
Neurobiol Dis. 45, 1121-1128 
87 Carmichael, S. L., Ma, C., Choudhry, S., Lammer, E. J., Witte, J. S. and Shaw, G. M. (2013) 
Hypospadias and genes related to genital tubercle and early urethral development. J Urol. 190, 1884-1892 
88 Bansal, H., Yihua, Q., Iyer, S. P., Ganapathy, S., Proia, D. A., Penalva, L. O., Uren, P. J., Suresh, 
U., Carew, J. S., Karnad, A. B., Weitman, S., Tomlinson, G. E., Rao, M. K., Kornblau, S. M. and Bansal, 
S. (2014) WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia. 28, 1171-1174 
89 Jo, H. J., Shim, H. E., Han, M. E., Kim, H. J., Kim, K. S., Baek, S., Choi, K. U., Hur, G. Y. and 
Oh, S. O. (2013) WTAP regulates migration and invasion of cholangiocarcinoma cells. J Gastroenterol. 
48, 1271-1282 
90 Shahid, S. U., Shabana, Rehman, A. and Hasnain, S. (2016) Role of a common variant of Fat 
Mass and Obesity associated (FTO) gene in obesity and coronary artery disease in subjects from Punjab, 
Pakistan: a case control study. Lipids Health Dis. 15, 29 
Dezi et al. 23 
91 Tan, A., Dang, Y., Chen, G. and Mo, Z. (2015) Overexpression of the fat mass and obesity 
associated gene (FTO) in breast cancer and its clinical implications. Int J Clin Exp Pathol. 8, 13405-
13410 
92 Lin, Y. S., Ueda, J., Yagyu, K., Ishii, H., Ueno, M., Egawa, N., Nakao, H., Mori, M., Matsuo, K. 
and Kikuchi, S. (2013) Association between variations in the fat mass and obesity-associated gene and 
pancreatic cancer risk: a case-control study in Japan. Bmc Cancer. 13 
93 Du, T. F., Rao, S. Q., Wu, L., Ye, N., Liu, Z. Y., Hu, H. L., Xiu, J. B., Shen, Y. and Xu, Q. 
(2015) An association study of the m6A genes with major depressive disorder in Chinese Han population. 
Journal of Affective Disorders. 183, 279-286 
 
 
Dezi et al. 24 
Figure legends 
 
Figure 1 Nucleotide modifications in mRNA. A) Inosine, B) Pseudouridine, C) N6-
methyladenosine, D) N1-methyladenosine, E) 5-methylcytosine and F) 5-hydroxymethylcytosine 
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Table 1: Orthologues of mRNA modification enzymes in humans, flies, worms, yeast and 
plants. Orthologues are as annotated in flybase, or searched for in data bases of other organisms 
(http://flybase.org/, http://www.wormbase.org, https://www.arabidopsis.org/index.jsp and 
www.yeastgenome.org). n.d.: not determined. 
 
 
 Orthologues of mRNA modifying enzymes 
 H. sapiens  D. melanogaster C. elegans S. cerevisiae A. thaliana References  
mRNA modification 
A-to-I editing ADAR1 absent ADR-1  
 ADAR2 ADAR ADR-2 absent absent [2, 19] 
 ADAR3 absent absent 
 
Pseudouridylation DKC1 NOP60B K01G5.5 CBF5 AT3G57150 [21, 23-25, 82] 
 PUS1 CG4159 PUS1 PUS1 
 PUSL1 CG34140 Y73B6BL.29  
    PUS2 
 PUSD2 RluA-1/-2 K07E8.7 
 PUS3 CG3045 TAG-124 PUS3 
 PUS4 CG7849 Y43B11AR.3 PUS4 
 PUS6   PUS6 
 PUS7 CG6745 B0024.11 PUS7 
 PUS9  PUS9 PUS9 
 PUS10 CG3709 Y48C3A.20  
 
m6A methylation METTL3 dIME4 absent IME4 AT4G10760 [46, 53] 
 METTL14 dKAR4 absent KAR4 AT4G09980 
 
m1A methylation unknown n.d. n.d. unknown n.d. 
 
m5C methylation NSUN2 NSUN2 Y48G8AL.5 TRM4 AT2G22400 [70, 80] 
 
hm5C hydroxylation TET3 dTET absent absent absent [79-81] 
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Table 2: Human diseases associated with mRNA modification genes. 
 
mRNA modification Gene Human disorder  
 
I  adar1 (adenosine deaminase, RNA-specific, 1) Chronic myeloid leukemia (CML)[19] 
   Metastatic melanoma[15] 
   Human hepatocellular carcinoma(HCC)[83] 
   Esophageal squamous cell carcinoma (ESCC)[17] 
   Dyschromatosis symmetrica heriditaria (DSH)[84] 
   Aicardi- Goutieres syndrome (AGS)[11] 
 
 adar2 (adenosine deaminase, RNA-specific, 2) Glioblastoma multiforme (GBM)[16] 
   Alzheimer disease[85] 
   Amyotrophic lateral sclerosis (ALS)[86] 
 
Ψ dkc1 (dyskerin pseudouridine synthase 1) Diskeratosis congenital[27] 
   Pituitary tumorigenesis[28] 
   Prostate cancer[29] 
 
 pus1 (pseudouridine synthase 1) Mitocondrial myopathy, lactic acidosis and sideroblastic anemia 
   (MLASA)[30] 
 
m6A  wtap (Wilms tumor 1 associated protein) Hypospadias[87] 
   Acute myelogennous leukemia (AML) [88] 
   Cholangiocarcinoma[89] 
 
 fto (fat mass- and obesity-associated gene) Obesity[63] 
   Coronary heart disease (CAD)[90] 
   Growth retardation, development delay and facial dysmorfism[64] 
   Type 2 diabetes [65] 
   Cancer[91] [92] 
 
 alkbh5 (alkB homolog 5, RNA demethylase) Infertility[62] 
   Major depressive disorder (MDD) [93] 
 
m5C nsun2 (nol1/nop2/sun domain family, member 2) Breast cancer [74] 
   Autosomal- recessive intellectual disability [78] 
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